3 Things You Should Expect in Gilead Sciences' Q3 Results
Things are looking up for Gilead Sciences (NASDAQ: GILD) for the first time in quite a while. Although the big biotech stock fell in the first half of 2017, its share price is up big since late June. Gilead announced better-than-expected results for its second quarter in July. And the company announced a much-anticipated acquisition in August with its deal to buy Kite Pharma.
Gilead provides an update on its third-quarter performance after the market closes on Thursday, Oct. 26. Can the biotech keep its momentum going? Here are three things you should expect in Gilead's third-quarter results.
Image source: Getty Images.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€15.80
1.610%
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 18 € there is a slightly positive potential of 13.92% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.8 €.
